Angiotensin II: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 1, 2026🚩 Report this page

Angiotensin II

Other Cardiac Stimulants

Sold as Giapreza

GB MHRAEU EMA

Drug class: Other Cardiac Stimulants
Availability: See label
Markets covered: 2
Products on record: 2

Overview

Angiotensin II is an active pharmaceutical ingredient in the Other Cardiac Stimulants group (C01CX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	May 1, 2026
EU European Union	EMA	1	September 25, 2024

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised May 1, 2026[1]

1).

How to take

GBOfficial regulatory label· revised May 1, 2026

EUEuropean Union· EMA

1 product

Uses

EUOfficial regulatory label· revised September 25, 2024[2]

1).

How to take

EUOfficial regulatory label· revised September 25, 2024

Drug interactions

Known interactions involving Angiotensin II. Select one for details. This list is informational and not a complete interaction checker.

Azilsartan Benazepril Captopril Enalapril Eprosartan Fosinopril Irbesartan Lisinopril Losartan Moexipril Olmesartan Perindopril Quinapril Ramipril Telmisartan Trandolapril Valsartan

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PLGB597680003 · revised May 1, 2026
[2]European Medicines Agency · EMEA/H/C/004930 · revised September 25, 2024

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 1, 2026[1]

Summary of the safety profile The adverse reactions described in this section were identified in the pivotal clinical trial (N = 163 treated with Giapreza). 9%) respectively. Tabulated list of adverse reactions Table 1 lists the adverse reactions recorded in clinical trials in the total safety population treated with Giapreza by MedDRA system organ class and frequency.
Frequency categories are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), and very rare (< 1/10 000).
Table 1:
Frequency of adverse reactions MedDRA System organ class Very common Common Cardiac disorders Tachycardia Vascular disorders Thromboembolic eventsa Transient hypertensionb Peripheral ischaemia a Grouped term to include arterial and venous thrombotic events b Defined as an increase in mean arterial pressure > 100 mmHg Description of selected adverse reactions Transient hypertension A total of 37 patients (23%) experienced transient hypertension with the angiotensin II 20 ng/kg/min starting dose.
2). 1%]). 1%] vs 0 [0%] respectively). Of these, 7 cases corresponded to deep vein thrombosis. 2%) patients in the Giapreza arm experienced a fatal thromboembolic event compared with no patients in the placebo arm. 4). 5%]). 9%) cases in the placebo arm were considered serious.
One patient in each arm discontinued treatment as a result. Peripheral ischaemia may be a consequence of the mechanism of action of Giapreza. It is important to administer Giapreza at the lowest compatible dose to achieve or maintain adequate mean arterial pressure and tissue perfusion.
4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 1, 2026[1]

The clinical experience with Giapreza is limited to septic or other distributive shock. g. 1). Thromboembolic events Thromboembolic events have been reported with the use of angiotensin II in clinical trials. 8). Concurrent venous thromboembolism (VTE) prophylaxis should be used unless contraindicated during treatment with Giapreza.
Non-pharmacologic VTE prophylaxis may be considered where pharmacologic prophylaxis is contraindicated. 8). It is important to administer Giapreza at the lowest compatible dose to achieve or maintain adequate mean arterial pressure and tissue perfusion.
2). 5 mg/ml, that is to say essentially ‘sodium-free’.

This is not medical advice. Consult a qualified healthcare professional.

Side effects & warnings

EUOfficial regulatory label· Adverse reactions· revised September 25, 2024[2]

Summary of the safety profile The adverse reactions described in this section were identified in the pivotal clinical trial (N = 163 treated with Giapreza). 9%) respectively. Tabulated list of adverse reactions Table 1 lists the adverse reactions recorded in clinical trials in the total safety population treated with Giapreza by MedDRA system organ class and frequency.
Frequency categories are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), and very rare (< 1/10 000).
Table 1:
Frequency of adverse reactions MedDRA System organ class Very common Common Cardiac disorders Tachycardia Vascular disorders Thromboembolic eventsa Transient hypertensionb Peripheral ischaemia a Grouped term to include arterial and venous thrombotic events b Defined as an increase in mean arterial pressure > 100 mmHg Description of selected adverse reactions Transient hypertension A total of 37 patients (23%) experienced transient hypertension with the angiotensin II 20 ng/kg/min starting dose.
2). 1%]). 1%] vs 0 [0%] respectively). Of these, 7 cases corresponded to deep vein thrombosis. 2%) patients in the Giapreza arm experienced a fatal thromboembolic event compared with no patients in the placebo arm. 4). 5%]). 9%) cases in the placebo arm were considered serious.
One patient in each arm discontinued treatment as a result. Peripheral ischaemia may be a consequence of the mechanism of action of Giapreza. It is important to administer Giapreza at the lowest compatible dose to achieve or maintain adequate mean arterial pressure and tissue perfusion.
4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
6

EUOfficial regulatory label· Warnings and precautions· revised September 25, 2024[2]

The clinical experience with Giapreza is limited to septic or other distributive shock. g. 1). Thromboembolic events Thromboembolic events have been reported with the use of angiotensin II in clinical trials. 8). Concurrent venous thromboembolism (VTE) prophylaxis should be used unless contraindicated during treatment with Giapreza.
Non-pharmacologic VTE prophylaxis may be considered where pharmacologic prophylaxis is contraindicated. 8). It is important to administer Giapreza at the lowest compatible dose to achieve or maintain adequate mean arterial pressure and tissue perfusion.
2). 5 mg/ml, that is to say essentially ‘sodium-free’.

This is not medical advice. Consult a qualified healthcare professional.